A股异动 | 迪安诊断(300244.SZ)放量涨停 股价创近一年半新高
格隆汇9月19日丨迪安诊断(300244.SZ)午后放量涨停,股价创近一年半新高。现报26.02元,涨10.02%,成交量放大至5.97亿元,最新总市值161.443亿元。公司是国内领先的以提供诊断服务外包为核心业务的第三方独立医学诊断服务机构。近年来公司业绩增长良好,今年上半年公司营业收入39.94亿元,同比增长35.17%;扣非归母净利润2.28亿元,同比增长17.52%。国联证券日前称,公司各业务稳步发,,现金流改善明显。此外,公司与泰格合建观合医药布局CRO业务,目前已取得明显突破和进展。9月初热景生物科创版IPO注册生效,与迪安诊断达成战略合作,发挥互补优势,在更多领域开展务实合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.